We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
+31.58%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$250M
AUM Growth
+$80.2M
(+47%)
Cap. Flow
+$54.1M
Cap. Flow
% of AUM
21.67%
Top 10 Holdings %
Top 10 Hldgs %
36.89%
Holding
128
New
62
Increased
6
Reduced
21
Closed
36
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Inspire Medical Systems
INSP
|
+$6.46M |
| 2 |
HOLX
Hologic
HOLX
|
+$3.37M |
| 3 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$2.9M |
| 4 |
STAAR Surgical
STAA
|
+$2.34M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$2.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$4.14M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$4.09M |
| 3 |
Abbott
ABT
|
+$3.63M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$3.54M |
| 5 |
Globus Medical
GMED
|
+$3.52M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37.06% |
| 2 | Industrials | 1.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
CALL
Glaukos
GKOS
$10.7B
| $3.1M | 1.24% |
+76,200
| New | +$2.71M |
|
|
VRAY
27
DELISTED
ViewRay, Inc.
VRAY
| $3M | 1.2% |
433,315
+11,315
| +3% | +$82.2K |
|
28
Baxter International
BAX
$14.4B
| $2.95M | 1.18% |
40,000
-35,000
| -47% | -$2.47M |
|
|
SYNH
29
CALL
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $2.81M | 1.13% |
+60,000
| New | +$2.48M |
|
|
SPPI
30
CALL
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $2.74M | 1.1% |
130,700
+30,700
| +31% | +$569K |
|
|
XENT
31
DELISTED
Intersect ENT, Inc
XENT
| $2.71M | 1.09% |
72,500
-37,500
| -34% | -$1.47M |
|
32
CALL
Viatris
VTRS
$18.7B
| $2.71M | 1.09% |
+75,000
| New | +$2.94M |
|
|
NSTG
33
DELISTED
NanoString Technologies, Inc.
NSTG
| $2.71M | 1.09% |
+198,117
| New | +$2.27M |
|
|
XENT
34
PUT
DELISTED
Intersect ENT, Inc
XENT
| $2.62M | 1.05% |
+70,000
| New | +$2.75M |
|
|
35
Vertex Pharmaceuticals
VRTX
$133B
| $2.55M | 1.02% |
+15,000
| New | +$2.33M |
|
|
SIEN
36
CALL
DELISTED
Sientra, Inc.
SIEN
| $2.45M | 0.98% |
12,540
-37,820
| -75% | -$6M |
|
37
DexCom
DXCM
$33.1B
| $2.38M | 0.95% |
100,000
-48,560
| -33% | -$1.03M |
|
|
IVC
38
DELISTED
Invacare Corporation
IVC
| $2.28M | 0.92% |
122,735
-154,061
| -56% | -$2.79M |
|
|
GBT
39
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $2.26M | 0.91% |
+50,000
| New | +$2.28M |
|
40
CALL
Accuray
ARAY
$34.9M
| $2.25M | 0.9% |
550,000
+250,000
| +83% | +$1.16M |
|
|
ZGNX
41
CALL
DELISTED
Zogenix, Inc.
ZGNX
| $2.21M | 0.89% |
+50,000
| New | +$2.06M |
|
42
Sarepta Therapeutics
SRPT
$1.81B
| $2.12M | 0.85% |
+16,000
| New | +$1.51M |
|
|
SPPI
43
PUT
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $2.1M | 0.84% |
+100,000
| New | +$1.85M |
|
|
44
Glaukos
GKOS
$10.7B
| $2.03M | 0.81% |
50,000
+10,000
| +25% | +$356K |
|
|
ZGNX
45
DELISTED
Zogenix, Inc.
ZGNX
| $2M | 0.8% |
45,268
-5,000
| -10% | -$206K |
|
|
HOLX
46
CALL
DELISTED
Hologic
HOLX
| $1.99M | 0.8% |
+50,000
| New | +$1.92M |
|
47
OrthoPediatrics
KIDS
$608M
| $1.98M | 0.79% |
+74,385
| New | +$1.59M |
|
48
ProQR Therapeutics
PRQR
$255M
| $1.98M | 0.79% |
+271,159
| New | +$1.37M |
|
|
WMGI
49
DELISTED
Wright Medical Group Inc
WMGI
| $1.95M | 0.78% |
+75,000
| New | +$1.71M |
|
|
TVRD
50
CALL
Tvardi Therapeutics
TVRD
$22M
| $1.92M | 0.77% |
+2,778
| New | +$1.41M |
|
Similar funds
BCA
RC
DOFI
SR
SCI
LPC
GBCP
SCTC
Pura Vida Investments's Q2 2018 Portfolio in Review
As of Q2 2018, Pura Vida Investments held 128 positions worth $250M, up 47% from $169M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Pura Vida Investments deployed $54.1M of net new capital in Q2 2018, opening 62 new positions and adding to 6 existing holdings. Its largest new stake was Inspire Medical Systems: 200,280 shares worth $7.14M.
By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 52% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was Merck, an estimated $4.14M trimmed.
- Pura Vida Investments's largest Q2 2018 buy was Inspire Medical Systems: 200,280 shares worth $7.14M.
- Pura Vida Investments added most to Allergan plc in Q2 2018, an estimated $1.61M increase.
- Pura Vida Investments's biggest Q2 2018 reduction was Merck, cutting an estimated $4.14M.
- Pura Vida Investments fully exited Abbott in Q2 2018, selling an estimated $3.63M.
- Pura Vida Investments's ten largest holdings make up 37% of its $250M portfolio in Q2 2018.
- Pura Vida Investments opened 62 new positions and closed 36 in Q2 2018.
- Pura Vida Investments's portfolio value rose 47% quarter-over-quarter to $250M.
Based on Pura Vida Investments's 13F filing for Q2 2018, filed 14 Aug 2018.